AbCellera Biologics (ABCL) Scheduled to Post Earnings on Tuesday

AbCellera Biologics (NASDAQ:ABCLGet Free Report) will be posting its quarterly earnings results after the market closes on Tuesday, February 20th. Analysts expect AbCellera Biologics to post earnings of ($0.14) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

AbCellera Biologics Trading Up 6.8 %

Shares of NASDAQ ABCL opened at $5.46 on Tuesday. The stock has a market cap of $1.58 billion, a P/E ratio of -12.13 and a beta of 0.38. AbCellera Biologics has a 12-month low of $3.87 and a 12-month high of $10.21. The business’s fifty day simple moving average is $5.36 and its 200-day simple moving average is $5.12.

Hedge Funds Weigh In On AbCellera Biologics

Hedge funds have recently made changes to their positions in the company. Worth Asset Management LLC purchased a new position in shares of AbCellera Biologics during the first quarter worth about $25,000. Point72 Asset Management L.P. purchased a new position in shares of AbCellera Biologics during the second quarter worth about $26,000. Point72 Middle East FZE purchased a new position in shares of AbCellera Biologics during the second quarter worth about $30,000. Belpointe Asset Management LLC grew its holdings in shares of AbCellera Biologics by 55.7% during the first quarter. Belpointe Asset Management LLC now owns 5,300 shares of the company’s stock worth $40,000 after buying an additional 1,896 shares during the last quarter. Finally, Citigroup Inc. grew its holdings in shares of AbCellera Biologics by 56.1% during the second quarter. Citigroup Inc. now owns 8,021 shares of the company’s stock worth $52,000 after buying an additional 2,884 shares during the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ABCL. Bloom Burton restated a “buy” rating on shares of AbCellera Biologics in a research note on Friday, November 3rd. KeyCorp began coverage on AbCellera Biologics in a research note on Tuesday, December 5th. They issued an “overweight” rating and a $6.00 price target on the stock. Finally, Benchmark cut AbCellera Biologics from a “buy” rating to a “hold” rating in a research note on Monday, November 6th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.38.

Check Out Our Latest Stock Analysis on ABCL

About AbCellera Biologics

(Get Free Report)

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets.

Recommended Stories

Earnings History for AbCellera Biologics (NASDAQ:ABCL)

Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.